Collective efforts by civil society groups bar the way to Hepatitis C patents
Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position...
Civil society key in TRIPS flexibility implementation
Civil society plays an instrumental role in actively defending access to affordable to medicines, making use of TRIPS flexibilities, and...
Gilead’s patent application on sofosbuvir rejected in Brazil
Rejected! That was the decision issued by Brazil’s National Institute of Industrial Property (INPI) over one of Gilead’s patent applications...
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: Malaysia Ministry of Health 2018 winner of the Leadership Award on Intellectual Property and Access to Medicines
Malaysia’s “historic decision” to issue a compulsory license on Hep C medicine, sofosbuvir, stands up to Big Pharma, and will mean...
Argentina: Patent rejected on hepatitis C drug, sofosbuvir
A decision by the patent office in Argentina (INPI) to reject Gilead’s patent on key hepatitis C drug, sofosbuvir, is...
São Paulo protest exposes how Gilead’s actions block access to medicines around the world
In São Paulo, on 31 October 2017, activists from around the world held a protest at the headquarters of...
The Indonesian patent club – and its impact on Hep C treatment
Communities are refusing to accept patent abuse – challenging unmerited patents, and finding ways around them in the meantime. Community...
Myanmar: Creating an intellectual property law that protects public health
Lobbying for an intellectual property law that doesn’t just serve big business, but protects public health and encourages innovation in...